Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B

Hepatology

Volumn 40, Issue 4, 2004, Pages 865-873

  Garfein, Richard S ^a   Bower, William A ^a   Loney, Cherry M ^b   Hutin, Yvan J F ^a   Xia, Guo Liang ^a   Jawanda, Jaspaul ^a   Groom, Amy V ^c   Nainan, Omana V ^a   Murphy, James S ^d   Bell, Beth P ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Cascade City County Hlth Department   (United States)

^c INDIAN HEALTH SERVICE   (United States)

^d MONTANA DEPARTMENT OF PUBLIC HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ILLICIT DRUG; METHAMPHETAMINE; PARACETAMOL;

ACUTE HEPATITIS; ADULT; ALCOHOL CONSUMPTION; AMERICAN INDIAN; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DRUG USE; EPIDEMIC; FATALITY; FEMALE; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER FAILURE; LIVER INJURY; MALE; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; UNITED STATES; VIRUS GENOME; WEIGHT REDUCTION;

ACUTE DISEASE; ADULT; CASE-CONTROL STUDIES; DISEASE OUTBREAKS; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER FAILURE; MALE; MIDDLE AGED; MONTANA; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS;

EID: 4644316318     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20383     Document Type: Article

References (49)

1. Krugman S, Overby LR, Mushahwar IK, Ling CM, Frosner GG, Deinhardt F. Viral hepatitis, type B. Studies on natural history and prevention re-examined. N Engl J Med 1979;300:101-106.
2. Lee WM. Acute liver failure. N Engl J Med 1993;329:1862-1872.
3. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.
4. Centers for Disease Control and Prevention. Hepatitis B-New Bern, North Carolina. MMWR Morb Mortal Wkly Rep 1979;28:373-374.
5. Centers for Disease Control and Prevention. Fulminant hepatitis B among parenteral drug abusers-Kentucky, California. MMWR Morb Mortal Wkly Rep 1984;33:70-77.
6. Hadler SC, De Monzon M, Ponzetto A, Anzola E, Rivero D, Mondolfi A, et al. Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela. Ann Intern Med 1984;100:339-344.
7. Goldfinger R, Ahmed KS, Pitchumoni CS, Weseley SA. Concomitant alcohol and drug abuse enhancing acetaminophen toxicity. Report of a case. Am J Gastroenterol 1978;70:385-388.
8. Licht H, Seeff LB, Zimmerman HJ. Apparent potentiation of acetaminophen hepatotoxicity by alcohol. Ann Intern Med 1980;92:511.
9. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. HEPATOLOGY 2000;31:1037-1044.
10. de Man RA, Sprey RP, Niesters HG, Heijtink RA, Zondervan PE, Hop W, et al. Survival and complications in a cohort of patients with anti-delta positive liver disease presenting in a tertiary referral clinic. J Hepatol 1995;23:662-667.
11. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-661.
12. Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am J Epidemiol 1995;142:331-341.
13. Substance Abuse and Mental Health Services Administration. Results from the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National Findings. Rockville, MD: SAMSA, Office of Applied Studies,; 2002. NHSDA Series H-17, DHHS Publication No. SMA 02-3758.
14. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 58. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2003:25-37.
15. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. J Am Med Assoc 1990;263:1218-1222.
16. Nainan OV, Cromeans TL, Margolis HS. Sequence-specific, single-primer amplification and detection of PCR products for identification of hepatitis viruses. J Virol Methods 1996;61:127-134.
17. Prescott LF, Roscoe P, Wright N, Brown SS. Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet 1971;1:519-522.
18. Campos FJ, Martinez RC, Perez BE, Gonzalez QA. Cocaine related fulminant liver failure. An Med Interna 2002;19:365-367.
19. Kanel GC, Cassidy W, Shuster L, Reynolds TB. Cocaine-induced liver cell injury: comparison of morphological features in man and in experimental models. HEPATOLOGY 1990;11:646-651.
20. Jones AL, Jarvie DR, McDermid G, Proudfoot AT. Hepatocellular damage following amphetamine intoxication. J Toxicol Clin Toxicol 1994;32:435-444.
21. Kamijo Y, Soma K, Nishida M, Namera A, Ohwada T. Acute liver failure following intravenous methamphetamine. Vet Hum Toxicol 2002;44:216-217.
22. Andreu V, Mas A, Bruguera M, Salmeron JM, Moreno V, Nogue S, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 1998;29:394-397.
23. Jonas MM, Hoppin AG, Graeme-Cook FM. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2001. A 17-year-old girl with marked jaundice and weight loss. N Engl J Med 2001;344:591-599.
24. Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 1999;13:129-133.
25. Carvalho F, Remiao F, Amado F, Domingues P, Correia AJ, Bastos ML. d-Amphetamine interaction with glutathione in freshly isolated rat hepatocytes. Chem Res Toxicol 1996;9:1031-1036.
26. Pessayre D, Dolder A, Artigou JY, Wandscheer JC, Descatoire V, Degott C, et al. Effect of fasting on metabolite-mediated hepatotoxicity in the rat. Gastroenterology 1979;77:264-271.
27. Price VF, Jollow DJ. Mechanism of decreased acetaminophen glucuronidation in the fasted rat. Biochem Pharmacol 1988;37:1067-1075.
28. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. J Am Med Assoc 1994;272:1845-1850.
29. Poison JE, Ponsiano O, Larson AM, Hyman L, Lalani EK, Harrison ME, et al. Role of acetaminophen in acute liver failure due to viral hepatitis [Abstract]. HEPATOLOGY 2003;38(Suppl 1):544A.
30. Rezende G, Roque-Afonso AM, Samuel D, Gigou M, Nicand E, Ferre V, et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection [Comment]. HEPATOLOGY 2003;38:613-618.
31. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994;68:1651-1659.
32. Kaneko M, Uchida T, Moriyama M, Arakawa Y, Shikata T, Gotoh K, et al. Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B. J Med Virol 1995;47:204-208.
33. Ogata N, Miller RH, Ishak KG, Purcell RH. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 1993;194:263-276.
34. Asahina Y, Enomoto N, Ogura Y, Sakuma I, Kurosaki M, Izumi N, et al. Complete nucleotide sequences of hepatitis B virus genomes associated with epidemic fulminant hepatitis. J Med Virol 1996;48:171-178.
35. Petrosillo N, Ippolito G, Solforosi L, Varaldo PE, Clementi M, Manzin A. Molecular epidemiology of an outbreak of fulminant hepatitis B. J Clin Microbiol 2000;38:2975-2981.
36. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995;122:241-248.
37. Sterneck M, Kalinina T, Otto S, Gunther S, Fischer L, Burdelski M, et al. Neonatal fulminant hepatitis B: structural and functional analysis of complete hepatitis B virus genomes from mother and infant. J Infect Dis 1998;177:1378-1381.
38. Chen Y, Michitaka K, Matsubara H, Yamamoto K, Horiike N, Onji M. Complete genome sequence of hepatitis B virus (HBV) from a patient with fulminant hepatitis without precore and core promoter mutations: comparison with HBV from a patient with acute hepatitis infected from the same infectious source. J Hepatol 2003;38:84-90.
39. Yotsumoto S, Kojima M, Shoji I, Yamamoto K, Okamoto H, Mishiro S. Fulminant hepatitis related to transmission of hepatitis B variants with precore mutations between spouses. HEPATOLOGY 1992;16:31-35.
40. Liang TJ, Hasegawa K, Munoz SJ, Shapiro CN, Yoffe B, McMahon BJ, et al. Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation. J Clin Invest 1994;93:550-555.
41. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-1709.
42. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996;70:5845-5851.
43. Moriyama K, Okamoto H, Tsuda F, Mayumi M. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 1996;226:269-280.
44. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promoter mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996;98:2268-2276.
45. Li J, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol 1999;73:1239-1244.
46. Centers for Disease Control and Prevention. Hepatitis B and injecting-drug use among American Indians-Montana, 1989-1990. MMWR Morb Mortal Wkly Rep 1992;41:13-14.
47. Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep 1982;31:317-22.
48. Centers for Disease Control and Prevention. Hepatitis B vaccination among high-risk adolescents and adults-San Diego, California, 1998-2001. MMWR Morb Mortal Wkly Rep 2002;51:618-621.
49. Centers for Disease Control and Prevention. Hepatitis B vaccination for injection drug users-Pierce County, Washington, 2000. MMWR Morb Mortal Wkly Rep 2001;50:388-390.